ARWR Stock Summary

• For ARWR, its debt to operating expenses ratio is greater than that reported by just 0.39% of US equities we're observing.
• With a year-over-year growth in debt of -100%, Arrowhead Pharmaceuticals Inc's debt growth rate surpasses only 0% of about US stocks.
• Revenue growth over the past 12 months for Arrowhead Pharmaceuticals Inc comes in at 905.49%, a number that bests 99.14% of the US stocks we're tracking.
• If you're looking for stocks that are quantitatively similar to Arrowhead Pharmaceuticals Inc, a group of peers worth examining would be CRBP, XNCR, AFMD, VYGR, and CRSP.
• Visit ARWR's SEC page to see the company's official filings. To visit the company's web site, go to arrowheadpharma.com.